SKYE faces severe financial deterioration with cash reserves plummeting from $68.4M to $5.9M while operating losses nearly doubled and the company completed an acquisition of Bird Rock Bio.
The dramatic cash burn combined with substantially higher operating losses raises immediate liquidity concerns for this clinical-stage biotech company. With only $5.9M in cash remaining and operating cash flow deeply negative, SKYE appears to face near-term funding pressures that could impact its ability to complete ongoing clinical trials and operations.
SKYE's financial position deteriorated markedly, with cash and equivalents falling 91% to just $5.9M while operating losses expanded substantially to $58.2M. The company's balance sheet contracted significantly, with total assets declining 61% and stockholders' equity dropping 71%, while liabilities increased nearly 80%. This financial profile suggests acute liquidity stress for a clinical-stage company that requires substantial ongoing cash to fund drug development operations.
Capex reduced 99.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Cash declined 91.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current liabilities surged 89.1% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 79.7% — significant increase in debt or obligations, assess impact on financial flexibility.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Operating cash flow fell 70.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Current assets declined 61.7% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 61.1% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →